Login / Signup

Use of tofacitinib in baricitinib-refractory atopic dermatitis: An example of JAK inhibitor switching.

Bhawuk DhirSumitra Kumari MeenaKabir SardanaSavitha Sharath
Published in: Pediatric dermatology (2023)
Atopic dermatitis (AD) is predominantly mediated by a T-helper 2 immune system response. While JAK inhibitors have gained treatment approval for AD, data regarding interclass efficacy and therapeutic rationale is lacking. We report a patient with recalcitrant AD who failed baricitinib but demonstrated an excellent response to the pan-JAK inhibitor tofacitinib.
Keyphrases
  • atopic dermatitis
  • rheumatoid arthritis
  • ulcerative colitis
  • case report
  • clinical trial
  • electronic health record
  • regulatory t cells
  • dendritic cells
  • combination therapy
  • deep learning
  • drug administration